ROCHE HOLDING AG
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 4 Sell calls were followed by roughly flat moves (+2%) three months out.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 53.37
- Open
- 53.84
- Day range
- 53.66 - 54.17
- Avg price
- --
- Volume
- 175.58K
- Turnover
- 9.50M
- Turnover ratei
- 0.00%
- Amplitudei
- 0.96%
- 52-week rangei
- 40.07 - 60.85
Valuation
- P/Ei
- --
- P/E (TTM)i
- 22.08
- P/Bi
- 8.74
- EPSi
- 2.45
- Book value / shi
- 6.19
- Net profit
- --
- Net assets
- --
Share structure
- Market cap
- 333.05B
- Float capi
- --
- Shares out
- 6.16B
- Float sharesi
- 6.16B
Dividend & listing
- Div yield (TTM)i
- 2.87%
- Dividend (TTM)
- 1.53
- Listing date
- 1970-01-01
11.1% below the 52-week high
Frequently asked questions
What is the current stock price of ROCHE HOLDING AG (RHHBY)?
ROCHE HOLDING AG last traded at 54.09. The quote on this page refreshes every few seconds while US markets are open.
What is ROCHE HOLDING AG's market cap?
About 333.05B.
What is the P/E ratio of ROCHE HOLDING AG?
The trailing twelve-month P/E is 22.08. The Valuation tab shows it against the stock's own five-year range.
Does ROCHE HOLDING AG pay a dividend?
Yes. The trailing dividend yield is 2.87%. See the Dividends tab for the full payment history.
What is ROCHE HOLDING AG's StockVane Quant Rating?
The StockVane Momentum strategy currently rates ROCHE HOLDING AG a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-12 05:30:29 · For reference only, not investment advice and not tailored to your situation.
diagnostics arm doesn’t get enough credit next to the pharma pipeline headlines. currency moves swing the adr price more than the underlying business most quarters.